The following information is for people with type 2 diabetes.
The possibility of a new long-acting insulin that would only require one injection per week is under trial. This has the potential to improve outcomes for patients who struggle with daily injections.
Once-weekly basal insulin analog Icodec by Novo Nordisk has shown comparable efficacy and safety to once-daily insulin glargine U100 according to phase 2 data published in the New England Journal of Medicine. Because of its concentrated formulation, its injection volume is equivalent to that of daily glargine U100 with a steady insulin release.
In the 26-week randomized phase 2 trial involving 247 patients with type 2 diabetes, once-weekly icodec’s glucose-lowering and safety profiles were similar to those of once-daily insulin glargine U100. In addition, new data in a poster at EASD(a large diabetes conference) showed that switching to icodec from other basal insulins is effective without causing significant hypoglycemia
For more information visit: https://www.medscape.com/viewarticle/937847
Back to October 2020 Newsletter
